

**DCAT**

# TOP Industry NEWS

*BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum.*

**Patheon**  
A HEALTHIER WORLD. DELIVERED.

Executive insights. Delivered.

[Learn more](#)

## 1. [Court Upholds Patent for Lilly's Blockbuster Vitamin Regimen](#)

Eli Lilly and Company has received a favorable court ruling upholding the validity and infringement of the vitamin regimen patent for Alimta (pemetrexed for injection), an anti-cancer drug. The drug is one of Lilly's top-selling products with approximately \$2.5 billion in 2015 sales. [Read More](#)

## 2. [Biogen in \\$1.25-Billion Settlement and License Agreement](#)

Biogen has agreed to a \$1.25-billion settlement and license agreement with Forward Pharma, a Copenhagen-based biopharmaceutical company, over a patent dispute involving intellectual property covering dimethyl fumarate, the active ingredient in Biogen's multiple sclerosis drug, Tecfidera. [Read More](#)

## 3. [Pfizer Opens Manufacturing Plant in Saudi Arabia](#)

Pfizer has opened a manufacturing facility in King Abdullah Economic City (KAEC), Saudi Arabia and has begun operations for producing 16 medicines at the plant. The facility represents an approximately \$50 million, or Saudi Arabian Riyal 187.5 million, investment to date by Pfizer. [Read More](#)

## 4. [Lilly to Acquire Migraine Drug Company in \\$960-Million Deal](#)

Eli Lilly and Company has agreed to acquire CoLucid Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company focused on migraine therapies, for \$46.50 per share or \$960 million in an all-cash transaction. The acquisition boosts Lilly's existing pain management portfolio. [Read More](#)

## 5. [FDA Issues Guidance on Biosimilar Interchangeability](#)

The FDA has published for public comment a draft guidance for demonstrating interchangeability between a biosimilar and its reference product. The guidance focuses on therapeutic protein products and gives an overview of scientific considerations in demonstrating interchangeability. [Read More](#)

## 6. [UK Pharma Associations Weigh in on Brexit](#)

Following the speech by the UK Prime Minister Theresa May this week on the plan for the UK to exit the European Union, the Association of the British Pharmaceutical Industry and the UK BioIndustry Association offered their perspectives from a pharmaceutical industry perspective. [Read More](#)

## 7. [FDA Accepts Mylan's Filing of a Biosimilar of Roche's Breast-Cancer Drug](#)

The FDA has accepted a biologics license application from Mylan and Biocon, a Bangalore, India-based biopharmaceutical company, for a proposed biosimilar of trastuzumab, the active ingredient in Roche's breast-cancer drug, Herceptin (trastuzumab). The news is part of DCAT Value Chain Insights' Pipeline News. [Read More](#)

## 8. [GSK Names New Global Pharma President, as Current President Departs](#)

GlaxoSmithKline has appointed Luke Miels as the new president of its global pharmaceuticals business with the upcoming departure of Abbas Hussain, who is leaving the company. [Read More](#)

#### 9. [Merck KGaA Names New Chief Procurement Officer](#)

Merck KGaA has appointed Joachim Christ as its new chief procurement officer, succeeding Friedhelm Felten, who will be moved to head the company's Pigments & Functional Materials business unit. [Read More](#)

#### 10. [PhRMA Names New Chairman](#)

The Pharmaceutical Research and Manufacturers of America (PhRMA) has named Joaquin Duato as the new chairman of PhRMA's board of directors. Mr. Duato is currently worldwide chairman, pharmaceuticals, Johnson & Johnson. [Read More](#)

---

### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)